An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits.
Patients with abetalipoproteinemia, a disease caused by defects in the microsomal triglyceride transfer protein (MTP), do not produce apolipoprotein B-containing lipoproteins. It was hypothesized that small molecule inhibitors of MTP would prevent the assembly and secretion of these atherogenic lipoproteins. To test this hypothesis, two compounds identified in a high-throughput screen for MTP inhibitors were used to direct the synthesis of a highly potent MTP inhibitor. This molecule (compound 9) inhibited the production of lipoprotein particles in rodent models and normalized plasma lipoprotein levels in Watanabe-heritable hyperlipidemic (WHHL) rabbits, which are a model for human homozygous familial hypercholesterolemia. These results suggest that compound 9, or derivatives thereof, has potential applications for the therapeutic lowering of atherogenic lipoprotein levels in humans.
Department of Metabolic Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543-4000, USA. Wetterau_John_R@msmail.bms.com
J R
JR
Wetterau
R E
RE
Gregg
T W
TW
Harrity
C
C
Arbeeny
M
M
Cap
F
F
Connolly
C H
CH
Chu
R J
RJ
George
D A
DA
Gordon
H
H
Jamil
K G
KG
Jolibois
L K
LK
Kunselman
S J
SJ
Lan
T J
TJ
Maccagnan
B
B
Ricci
M
M
Yan
D
D
Young
Y
Y
Chen
O M
OM
Fryszman
J V
JV
Logan
C L
CL
Musial
M A
MA
Poss
J A
JA
Robl
L M
LM
Simpkins
W A
WA
Slusarchyk
R
R
Sulsky
P
P
Taunk
D R
DR
Magnin
J A
JA
Tino
R M
RM
Lawrence
J K
JK
Dickson
S A
SA
Biller
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001055:Apolipoproteins B / Q000097:blood*; D001219:Aspartate Aminotransferases / Q000097:blood; D002352:Carrier Proteins / Q000037:antagonists & inhibitors*; D002784:Cholesterol / Q000097:blood*; D006224:Cricetinae; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D005449:Fluorenes / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D006938:Hyperlipoproteinemia Type II / Q000097:blood* / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008099:Liver / Q000378:metabolism; D051379:Mice; D010880:Piperidines / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D014280:Triglycerides / Q000097:blood* / Q000378:metabolism; D014407:Tumor Cells, Cultured
C115225:9-(((trifluoromethyl)amino)carbonyl)-9-(4-(4-(2-(trifluoromethyl)benzamido)piperidinyl)butyl)fluorene; D001055:Apolipoproteins B; D002352:Carrier Proteins; D005449:Fluorenes; D008055:Lipids; D008074:Lipoproteins; D010880:Piperidines; D014280:Triglycerides; C106092:microsomal triglyceride transfer protein; D002784:Cholesterol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase